Amanote Research
Register
Sign In
Vedolizumab for Inflammatory Bowel Disease: Changing the Game, or More of the Same?
United European Gastroenterology Journal
- United States
doi 10.1177/2050640614550672
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Gastroenterology
Date
September 22, 2014
Authors
Tim Raine
Publisher
SAGE Publications
Related search
Letter: Vedolizumab for Autoimmune Liver Disease Associated Inflammatory Bowel Disease-Authors’ Reply
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
Digestive Diseases and Sciences
Physiology
Gastroenterology
Letter: Vedolizumab for the Management of Inflammatory Bowel Disease in Patients After Liver Transplantation for Primary Sclerosing Cholangitis
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Vedolizumab Exposure in Pregnancy: Outcomes From Clinical Studies in Inflammatory Bowel Disease
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Review Article: Predictors of Response to Vedolizumab and Ustekinumab in Inflammatory Bowel Disease
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
One-Year Effectiveness and Safety of Vedolizumab Therapy for Inflammatory Bowel Disease: A Prospective Multicentre Cohort Study
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
The Treatment of Inflammatory Bowel Disease With 6-Mercaptopurine or Azathioprine
Alimentary Pharmacology and Therapeutics
Hepatology
Pharmacology
Gastroenterology
Vedolizumab in Paediatric Inflammatory Bowel Disease: A Retrospective Multi-Centre Experience From the Paediatric IBD Porto Group of ESPGHAN
Journal of Crohn's and Colitis
Medicine
Gastroenterology
Rifaximin for Inflammatory Bowel Disease
Digestive Diseases and Sciences
Physiology
Gastroenterology
